SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists

Acta Pharmacologica Sinica

Volumn 20, Issue 12, 1999, Pages 1103-1108

  Costa, Baibara ^a   Colleoni, Mariapia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Cannabinoids; Pain measurement; SR141716A; Stereotyped behavior

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; RIMONABANT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEFECATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; RAT; RECTUM TEMPERATURE; STEREOTYPY; TAIL FLICK TEST;

ANIMALS; CANNABINOIDS; DEFECATION; LOCOMOTION; MALE; PAIN THRESHOLD; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STEREOTYPED BEHAVIOR;

EID: 0032777297     PISSN: 02539756     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AL, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
3. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
4. Mailleux P, Vanderhaeghen J-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992; 48: 655-68.
5. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunoistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411.
6. Gérard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279: 129-34.
7. Kaminski NE, Abood M, Kessler FK, Martin BR, Schatz AR. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 1992; 42: 736-42.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LS, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
9. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminsky NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharrnacol 1995; 50: 83-90.
10. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-8.
11. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
12. Compton DR, Aceto MD, Lowe J, Martir: BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrccannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277: 586-94.
13. Rinaldi-Carmona M, Earth F, Heaulme M, Alonso R, Shire D, Congy C, et al. Biochemical and pharmacological characterization of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995; 56: 1941-7.
14. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
15. Costa B, Vailati S, Colleoni M. SR141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol 1999; 10: 327-31.
16. Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 1998; 284: 1209-17.
17. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941; 72: 218-26.
18. Pertwee RG. The ring test: a quantitative method for assessing the "cataleptic" effect of cannabis in mice. Br J Pharmacol 1972; 46: 753-63.
19. Calignano A, La Rana G, Makriyannis A, Lin SY, Beltramo M, Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 1997; 340: R7-R8.
20. Colombo G, Agabio R, Lobina C, Reali R, Gessa GL. Cannabinoid modulation of intestinal propulsion in mice. Eur J Pharmacol 1998; 344: 67-9.
21. Izzo AA, Mascolo N, Borrelli F, Capasso F. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 65-70.
22. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997; 121: 1557-66.
23. Pertwee RG, Fernando SR, Nash JE, Coutts AA. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 1996; 118: 2199-205.
24. Izzo AA, Mascolo N, Borrelli F, Capasso F. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol 1998; 124: 1363-8.
25. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998; 18: 451-7.
26. Richardson JD, Aanonsen L, Hargreaves KM. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997; 319: R3-R4.
27. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 393: 381-3.
28. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+) - WIN55,212 - 2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 1997; 221: 157-60.
29. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 1998; 813: 323-8.
30. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 1997; 8: 491-6.
31. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 1997; 334: R1-R2.
32. Milligan G, Bond RA, Lee M. Inverse agonism: pharmacological curiosity of potential therapeutic strategy? Trends Pharmacol Sci 1995; 16: 10-3.
33. Leff P. The two-state model of receptor activation. Trends Pharmacol Sci 1995; 16: 89-97.
34. Terranova JP, Storme JJ, Lafon N, Perio A, Rinaldi-Carmona M, Le Fur G, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR141716A. Psychopharmacology 1996; 126: 165-72.
35. MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW. Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol 1998; 124: 619-22.
36. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J Biol Chem 1997; 272: 22330-9.
37. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 1998; 54: 1064-72.